Select a Region North America

Biden Orders Additional 100 M Doses of J&J’s COVID-19 Vaccine

Date: March 11, 2021 | Country: UNITED STATES | Region: NORTH AMERICA | Type: Regulation | Keywords: #bla #covid19 #emergencyuseauthorization #fda #hhs #j&j #merck #supplyagreement 
#vaccination #vaccine

PRICENTRIC BRIEF:

  • Alongside the CEOs from Johnson & Johnson (J&J) and Merck, United States President Joe Biden announced yesterday that the U.S. Department of Health and Human Services (HHS) will be directed to purchase an additional 100 million doses of J&J’s COVID-19 vaccine
  • The new order ups U.S. orders of the vaccine to 200 million doses, enough to vaccinate 200 million people, considering J&J’s vaccine requires only one dose
  • Today’s announcement builds on a deal reached in August 2020 for 100 million doses of the vaccine for the U.S., which contained a provision allowing the government to purchase up to 200 million additional doses, and according to administration officials, the supply is not expected to be fulfilled until the second half (H2) of 2021

 

THE DETAILS

WASHINGTON, D.C., United States – Alongside the CEOs from Johnson & Johnson (J&J) and Merck, United States President Joe Biden announced yesterday that the U.S. Department of Health and Human Services (HHS) will be directed to purchase an additional 100 million doses of J&J’s COVID-19 vaccine.

The new order ups U.S. orders of the vaccine to 200 million doses, enough to vaccinate 200 million people, considering J&J’s vaccine requires only one dose.

Today’s announcement builds on a deal reached in August 2020 for 100 million doses of the vaccine for the U.S., which contained a provision allowing the government to purchase up to 200 million additional doses. However, Biden’s announcement yesterday is not a “done deal.”

In an emailed statement shared by the Wall Street Journal, J&J stated: “The U.S. government has the option to purchase additional doses under a subsequent agreement. We look forward to any further discussions with the U.S. government.”

According to administration officials, the supply is not expected to be fulfilled until the second half (H2) of 2021.

Biden intends to secure enough COVID-19 vaccine doses for every adult American by the end of May. These additional doses from J&J will help ramp up vaccine stocks in the U.S.

At the end of February, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to J&J for its single-dose COVID-19 vaccine to prevent COVID-19 in individuals aged 18 years and up.

The company announced it plans on filing a Biologics License Application (BLA) for the vaccine with the FDA later in 2021. In the meantime, it will collect further data on the vaccine while it’s in use, ahead of approval.

Merck will be helping J&J produce its vaccine through a deal orchestrated with assistance from the White House. By the end of the year, Merck plans to help double the manufacturing capacity of the vaccine.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.